Previous Article | Next Article 
Journal of Virology, March 2001, p. 2921-2928, Vol. 75, No. 6
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.6.2921-2928.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Spontaneous Activation of the Lytic Cycle in Cells
Infected with a Recombinant Kaposi's Sarcoma-Associated
Virus
Henri-Jacques
Delecluse,1,2,*
Manuela
Kost,1
Regina
Feederle,1,2
Lisa
Wilson,2 and
Wolfgang
Hammerschmidt1
Department of Gene Vectors, GSF-National Research Center
for Environment and Health, D-81377 Munich,
Germany,1 and Department of Pathology,
CRC Institute for Cancer Studies, University of Birmingham, B15 2TT
Birmingham, United Kingdom2
Received 31 May 2000/Accepted 11 December 2000
 |
ABSTRACT |
The genetic analysis of human herpesvirus 8 (HHV8), also termed
Kaposi's sarcoma-associated virus, has been hampered by severe difficulties in producing infectious viral particles and modifying the
viral genome. In this article, we report the successful cloning of the
HHV8 complete genome onto a prokaryotic F-plasmid replicon which allows
the propagation of the recombinant viral DNA in Escherichia coli. The insertion of the F-plasmid into the HHV8 genome
interrupts the ORF56 gene, whose expression product
by homology with
the Epstein-Barr virus BSLF1 gene
is supposed to be necessary for lytic DNA replication. After introduction of the recombinant HHV8 DNA
into 293 cells, early viral antigens are expressed, suggesting that
spontaneous lytic replication is initiated. However, completion of the
lytic program is prevented by the absence of the ORF56 protein, and a
quasi-latent state is established. Upon reintroduction of the ORF56
viral gene, the block is overcome and infectious HHV8 virions are
produced. As the recombinant HHV8 genome can be easily modified in
E. coli, this experimental system opens the way to an
extensive genetic analysis of other HHV8 functions.
 |
INTRODUCTION |
The discovery of the genome of a
herpesvirus in cells from a Kaposi's sarcoma lesion was a major
breakthrough in our understanding of the pathogenesis of this disease
(21). This virus, termed Kaposi's sarcoma-associated
herpesvirus or human herpesvirus 8 (HHV8), encodes a number of
cytokines (macrophage-inhibitory protein, interleukin-6, and interferon
regulatory factor), cyclin homologues, and G proteins that act as
growth factors or promote cell proliferation. As a consequence, any of
these gene products could potentially contribute to tumor cell growth
(1, 3, 4, 19, 25). Viral inhibitors of apoptosis and viral
proteins with transforming properties have also been identified, making
this virus a strong candidate for the etiological agent of Kaposi's
sarcoma and other virus-associated diseases (16, 26).
However, a number of basic questions concerning this virus are left
unanswered. First, the target cell of HHV8 is unknown, and even the
cell lineage of Kaposi's sarcoma is highly controversial. Second, the
proteins and genomic elements that control the activation and
completion of the viral lytic cycle are only partly understood. Finally, with the exception of a single report (11), all
data concerning the transforming potential of this virus have been derived from experiments with single viral gene products, and nothing
is known about the function of these gene products in the context of
the whole virus. In particular, it is unclear whether all or only
certain viral transforming proteins are required for cellular
transformation. In this article, we report the successful cloning of
the whole HHV8 genome in Escherichia coli as a recombinant F-factor-based plasmid which permits the generation of any viral mutant. We introduced the F-plasmid into ORF56 (21) of
HHV8 strain BC-3 (2), a gene that codes for a protein
required for DNA replication, as indicated by its homology to the
primase encoded by BSLF1 of Epstein-Barr virus (EBV) (10).
Using this system, we show that cells carrying the recombinant HHV8
genome spontaneously initiate the viral lytic cycle, but that
completion of the lytic cycle requires reintroduction of the ORF56 gene product.
 |
MATERIALS AND METHODS |
Cells.
293 is a human embryonic epithelial kidney cell line
transformed by the E1a and E1b proteins from adenovirus strain 5 (13). This cell line was grown in RPMI 1640-10% fetal
calf serum (Life Technologies, Eggenstein, Germany). The BC-3 cell line
is a body cavity lymphoma cell line that was shown to carry HHV8
(2). This cell line was propagated in RPMI 1640-20%
fetal calf serum.
Recombinant DNA plasmids.
p1919 is an F-factor-based
prokaryotic replicon that carries the F-factor origin of replication,
the chloramphenicol resistance gene, the partitioning genes A and B,
the hygromycin resistance cassette, and the gene that codes for the
green fluorescent protein, as described previously (6). To
provide the flanking regions for homologous recombination with the HHV8
genome, a DNA fragment (BC1 nucleotide coordinates 77407 to 87158) from
the HHV8 genome BC1 (21) was introduced into plasmid
pACYC177 cleaved with NheI to give p2388. The HHV8 genomic
fragment was obtained after SpeI partial digestion of the
GA21 HHV8 cosmid. p2388 encompasses ORF56 from HHV8, the homolog of the
BSLF1 gene of EBV. The entire plasmid p1919 was introduced into the
single SpeI site of p2388 to yield the final plasmid p2421
(see Fig. 1). p2421 was linearized with the PspL I
restriction enzyme. The AccI-XhoI fragment from
2388 that contains HHV8 ORF56 was further subcloned onto the pKRV
expression plasmid that carries a cytomegalovirus promoter (p2484).
DNA transfections.
Transfections of cell lines with plasmid
DNA were performed using lipid micelles or electroporation. For
electroporation, BC-3 cells (107 cells) were washed in RPMI
1640 without fetal calf serum, resuspended in 250 µl of the same
medium, and placed with 10 µg of p2421 plasmid DNA in 0.4-cm gap
electroporation cuvettes. Cells were transfected using an
electroporator (Bio-Rad Laboratories, Munich, Germany) at 230 V and 960 µF. In order to introduce the recombinant HHV8 genome into a
eukarotic cell host 2 × 105 293 cells were incubated
in Optimem minimal medium (Life Technologies, Eggenstein, Germany) for
4 h with 1 µg of the recombinant HHV8/F-plasmid embedded in
lipid micelles (Lipofectamine; Life Technologies). For completion
of the viral lytic cycle, 1 µg of p2484, which carries the ORF56
gene, was transfected into 2 × 105 293 cells, which
stably carry the HHV8/F-plasmid recombinant virus.
Hygromycin selection.
One day after transfection, BC3 cells
were plated on 96-well cluster plates at a concentration of
104 cells per well, and hygromycin (Calbiochem, Munich,
Germany) was added to the culture medium (300 µg/ml). One day after
infection or transfection of 293 cells in a six-well cluster plate,
cells were expanded in a large culture plate (150 mm diameter), and selection was started at a 100 µg of hygromycin per ml. Cells were
fed weekly with fresh RPMI1640 with the same hygromycin concentration.
Plasmid rescue in E. coli.
Circular DNA
molecules were extracted from 107 293 cells stably carrying
the HHV8/F-plasmid recombinant using a denaturation-renaturation method
as described (14). E. coli strain DH10B was
transformed with the extracted viral recombinant DNA by electroporation
(1,800 V, 25 µF, 100
). Cells were plated on agar plates
containing chloramphenicol (15 µg/ml) for selection.
Infections.
Infectious particles containing HHV8/F-plasmid
DNA were obtained from 293 cells or BC3 cells stably carrying this
construct and used to infect HHV8-negative 293 cells. Supernatants from 107 BC3/F cells (concentration of 106 cells per
ml) in which the lytic cycle had been induced with tetradecanoyl
phorbol acetate (TPA; 20 ng/ml final concentration) and butyrate (3 mM
final concentration) for 3 days were used for infections (15, 17,
27). Similarly 5 ml of supernatants was obtained 3 days after
transfection of 1 µg of p2484 into 2 × 105
293-HHV8/F cells in one well of a six-well cluster plate. 293 cells
(2 × 104) were infected with 1 ml of filtered
(0.45-µm pore size) infectious supernatants in a well from a 24-well
cluster plate. In some cases, 293 cells were then selected for
hygromycin resistance after expansion in large culture plates (150 mm
diameter) and fed once a week with RPMI 1640 containing 10% fetal calf serum.
Southern blot analysis and Gardella gel analysis.
The method
for Gardella gel electrophoresis followed by Southern blot
hybridization has been described previously (5, 12). We
used 10 µg of DNA for the Southern blot analysis and 106
cells per slot for the Gardella analysis. In both cases, a plasmid encompassing the F-plasmid or p2421 was radioactively labeled and used
as a probe.
Immunostaining.
Detection of the early antigen (ORF59) or of
the K8.1A/B late HHV8 antigen in 293 cells carrying the HHV8/F-plasmid
was performed using monoclonal antibodies specific to these proteins
(Advanced Biotechnologies, Columbia, Mass.), as described previously
(6).
 |
RESULTS |
Introduction of an F-plasmid into the HHV8 genome.
A
prerequisite for the manipulation of the HHV8 genome in E. coli cells is the introduction of a prokaryotic replicon into the
viral genome. Since herpesviruses possess a very large genome, we chose
the replicon of the F-plasmid, which is known to accept large DNA
inserts and to replicate stably in E. coli. The genes encoding hygromycin resistance and green fluorescent protein were included to yield plasmid p1919 (6). In order to promote
its homologous recombination with the viral genome, HHV8 flanking regions were added to the F-plasmid. We decided to insert the p1919
F-plasmid derivative into open reading frame 56 (ORF56) of HHV8. This
gene is the homologue of the BSLF1 EBV gene that is indispensable for
lytic viral DNA replication. As a consequence, the final viral mutant
is incompetent to replicate, but its defect can be easily complemented.
Towards this end, we constructed the final plasmid p2421, which carries
the backbone of p1919 flanked by HHV8 sequences of about 4 and 5.7 kbp
in length (BC1 coordinates 77407 to 81401 and 81402 to 87158) to target
the ORF56 locus (Fig. 1). The linearized
plasmid DNA fragment was then introduced into the BC-3 cell line, which
harbors several extrachromosomal copies of the HHV8 genome. Cells were
subjected to hygromycin selection (300 µg/ml) after plating in
96-well cluster plates.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of the construct used for
homologous recombination. A plasmid backbone consisting of the
F-plasmid replicon, the hygromycin resistance gene, and the gene for
green fluorescent protein (gfp) was flanked by HHV8 sequences situated
left and right from the SpeI site of the ORF56 gene.
Successful homologous recombination inserts the F-plasmid, the
hygromycin resistance gene, and the green fluorescent protein gene into
the ORF56 gene locus, leading to a knockout mutation of this gene. As
we used cosmids from HHV8 strain BC1 to generate the flanking sequences
and because this strain is known to show some sequence variation from
the BC-3 virus, we sequenced the entire 8-kb region around the
SpeI site contained in the ORF56 gene. The sequencing showed
only four minor variations compared to the published sequence
(21) (data not shown).
|
|
Four weeks after selection, more than 40 hygromycin-resistant cell
clones positive for green fluorescent protein were established
and
characterized by Southern blot analysis. One cell clone, termed
BC-3/F,
was found to carry the F-plasmid inserted correctly into
the HHV8
genome (Fig.
2). Cell culture supernatant
was harvested
from this cell clone after incubation with TPA and
butyrate. The
supernatant contained infectious virions, as indicated by
the
expression of green fluorescent protein after infection of 293
cells (data not shown). After selection with hygromycin (100 µg/ml),
seven 293 cell clones that carried the viral genome were obtained,
as
shown by a Gardella gel analysis (Fig.
3). None of these 293-HHV8/F
cell clones
spontaneously produced virions, as expected from the
insertional
mutagenesis of the ORF56 gene. Southern blot analysis
of one of these
293 HHV8/F cell clones (293 HHV8/F III) showed
that it contained
recombinant plasmids only, excluding a coinfection
with wild-type HHV8
(Fig.
2).


View larger version (80K):
[in this window]
[in a new window]
|
FIG. 2.
Southern blot analysis of bacterial and eukaryotic
cellular DNAs containing the recombinant HHV8/F-plasmid. (A) Schematic
representation of the expected restriction map after BamHI
digestion of wild-type HHV8 DNA (HHV8 BC1), p2421 plasmid that was used
for recombination, and recombinant HHV8/F-plasmid. The maps are deduced
from the published HHV8 sequence (BC1 strain). The sizes of the
expected fragments are indicated (in base pairs). (B) DNAs extracted
from bacterial cells containing HHV8/F-plasmid DNA,
hygromycin-resistant BC3 clone (BC3/F), or 293 cells stably carrying
the HHV8/F-plasmid after transfection (293 HHV8/F III) or infection
(293-T-HHV8/F VIII) were digested with BamHI and separated
on a 0.8% agarose gel. DNAs extracted from the BC3 cell line and the
p2421 plasmid were used as positive controls. After blotting, the DNAs
were hybridized with 32P-radiolabeled p2421 DNA. The 4.7-kb
signal is characteristic of wild-type HHV8 DNA and is disrupted by the
recombination, whereas the 2- and 12.1-kb fragments are generated by
the recombination. This Southern blot analysis shows that recombination
took place as expected and that the 293 HHV8/F III and 293-T-HHV8/F
VIII cell clones contain only the recombinant HHV8/F-plasmid. The
14.9-kb band, expected in all samples, is only partly identified by the
2421 probe, leading to weaker signals. The p2421 plasmid contains only
part of the BamHI 3.9-kb fragment from the HHV8 genome, (3.6 kb), as well as an additional fragment 3.5 kb in size that stems from
the plasmid replicon. The probe detects an additional 9-kb DNA fragment
in the BC3 cell lines that is absent from the recombinant viruses. This
fragment is not expected from the HHV8 sequence and possibly stems from
a modified episome subpopulation in the BC3 cell line.
|
|

View larger version (68K):
[in this window]
[in a new window]
|
FIG. 3.
Gardella gel analysis of hygromycin-resistant 293 cell
clones. 293 cells were infected with supernatants from induced BC3 cell
clones that contain the recombinant HHV8/F-plasmid. After hygromycin
selection, seven clones were analyzed for the presence of circular
molecules that carry the F-plasmid. After hybridization with a probe
specific for the F-plasmid, all cell lines proved to carry the
recombinant virus genome. No lytic replication could be definitely
assessed, and the faint signals observed most probably correspond to
nonspecific DNA degradation products that happen to migrate at the same
position. However, the origin of this signal cannot be definitely
assessed, as indicated by the question mark.
|
|
Recovery of recombinant virus genome in E. coli.
The 293-HHV8/F cell clones infected with supernatant from the BC-3/F
cell line and selected for hygromycin resistance contained extrachromosomal copies of the recombinant HHV8 genome, as shown in
Fig. 3. Rescue of these circular molecules from one of these clones
(293 HHV8/F III) gave rise to chloramphenicol-resistant E. coli cell clones that proved to contain the HHV8/F plasmid hybrid
(Fig. 4). Comparison of several
restriction enzyme DNA fragment patterns with those deduced from the
analysis of the published genomic HHV8 sequences (21)
unambiguously identified the rescued genome as being the complete
genome of HHV8. In a further step, we constructed an SpeI
library from the cloned HHV8/F-plasmid genome, which proved to contain
all SpeI fragments expected from the available sequence
(viral strain BC1). These clones themselves contained all expected
BamHI restriction sites. Partial sequencing of certain
SpeI subclones confirmed the successful cloning of the BC3
genome in E. coli (data not shown). However, analysis of the
recombinant viral genome with additional restriction enzymes showed
occasional divergence from the predictions obtained with the BC1 HHV8
sequence. Minor variation in sequences is expected from two different
viral strains.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 4.
Restriction analysis of recombinant HHV8 DNA. Circular
molecules were extracted from the hygromycin-resistant 293-HHV8/F III
cell clone that was identified as containing the entire HHV8/F-plasmid.
After electroporation into E. coli strain DH10B and
chloramphenicol selection, plasmid DNA was extracted and digested with
XhoI and BamHI.
|
|
Stable transfection of recombinant HHV8/F plasmid into 293 cells.
In order to ensure that the HHV8/F-plasmid carried the
complete viral genome and that passaging of the viral DNA in E. coli did not alter the ability of HHV8 to replicate and give rise
to progeny virus (see below), 293 cells were stably transfected with the recombinant HHV8/F-plasmid and selected with hygromycin. Eight clones, termed 293-T-HHV8/F cells, were isolated. The Southern blot
analysis of one of these clones showed that it carries the HHV8/F
plasmid in the absence of wild-type viral DNA, as expected (293-T-HHV8/F VIII) (Fig. 2).
293 HHV8/F cells spontaneously express the HHV8 ORF59 early
antigen.
Some members of the herpesvirus family, like herpes
simplex virus type 1, spontaneously enter the lytic cycle after
infection of their target cells. Propagation of the virus from one cell to another results in rapid multiplication and a dramatic increase in
virus titer. However, for gammaherpesviruses like EBV, spontaneous lytic replication rarely occurs in vitro and latent infection is the
rule. Although cell lines derived from tumor biopsies are predominantly
latently infected with HHV8, it does not necessarily mean that 293 cells can also carry the wild-type HHV8 in a latent form. However, as
the HHV8 recombinant virus has a mutated ORF56 gene, lytic replication
cannot proceed. ORF56 encodes the homologue of the EBV primase, which
is considered an early gene product and indispensable for herpesvirus
DNA lytic replication. The immediate-early and early stages of the EBV
lytic program are not dependent on the expression of BSLF1. If the
parallel between BSLF1 and ORF56 is correct, spontaneous activation of
the HHV8 lytic program in 293 cells should lead to expression of early
HHV8 genes upstream of ORF56. Using an antibody directed against the
ORF59 antigen, the homologue of the EBV early antigen BMRF1, 30% of
the 293 HHV8/F and of the 293-T-HHV8/F cell clones were found to
express this viral protein (Fig. 5). This
finding indicates that the initial events in the HHV8 lytic gene
expression cascade take place spontaneously in 293 cells.

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 5.
293 cells that carry the recombinant HHV8/F-plasmid
spontaneously enter the lytic cycle. 293-T-HHV8/F cells and 293-HHV8/F
cells were stained with an antibody specific for the early ORF59
protein. Fixed cells were incubated with a specific monoclonal antibody
and a second anti-mouse immunoglobulin antibody coupled to the
indocarbocyanine fluorochrome. Stained cells were visualized under UV
light. Magnification, ×100.
|
|
Transfection of ORF56 gene product leads to production of
infectious virions in 293 cells.
Next, we wished to test the
ability of both the 293 HHV8/F III and 293-T-HHV8/F VIII cell lines to
support the complete lytic phase of HHV8's life cycle. Transient
transfection of an expression plasmid encompassing the ORF56 gene into
these cells led to the production of infectious particles. Supernatants
derived from transfected cells were able to infect parental 293 cells,
as indicated by the expression of green fluorescent protein observed 3 days after infection (Fig. 6). Comparable
virus stocks could be obtained from both cell lines, 293-HHV8/F III and
293-T-HHV8/F VIII. The number of cells which were positive for green
fluorescent protein upon infection was 102 out of 105
infected 293 cells (average of three sets of experiments). This is in
the same range as what we observed with supernatants containing 105 EBV infectious particles per ml (6). It is
difficult to evaluate the virus titers in these supernatants because
the efficiency with which 293 cells can be infected with HHV8 is
unknown (20). In conclusion, the recombinant virus proved
to be fully functional in terms of production of infectious particles,
indicating that propagation of the complete HHV8 genome in E. coli preserved the viral functions, very similar to the situation
with EBV (6). However, after more than 2 months of
continuous culture, the ability of the 293-HHV8/F III and 293-T-HHV8/F
VIII cell clones to sustain viral lytic replication decreased. This
effect is probably linked to gradual silencing of viral promoters, as
incubation of these cells with butyrate in combination with
transfection of the p2484 expression plasmid led to the expression of
the K8.1A/B late gene product (Fig. 7).
Butyrate is a potent inhibitor of histone deacetylase, causing
transcriptional repression by chromatin condensation.

View larger version (111K):
[in this window]
[in a new window]
|
FIG. 6.
Infection of 293 cells with recombinant HHV8/F-plasmid
virus. The 293 HHV8/F III cell line (A) and the 293-T-HHV8/F VIII cell
line (B) were transfected with ORF56 cloned onto an expression plasmid.
After 3 days, the supernatants from these transfected cell lines were
incubated with HHV8-negative 293 cells. After 3 days green fluorescent
protein-positive, HHV8-infected 293 cells could be observed.
Magnification, ×100.
|
|

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 7.
Expression of K8.1 A/B late viral antigen in 293-HHV8/F
III cells. The 293 HHV8/F III cell line was transfected with ORF56
cloned onto an expression plasmid and simultaneously incubated with 3 mM sodium butyrate. After 3 days in culture, cells were stained with an
antibody specific to the late K8.1 A/B viral protein. Fixed cells were
incubated with a specific monoclonal antibody to this antigen and a
second anti-mouse immunoglobulin antibody coupled to the
indocarbocyanine fluorochrome. Stained cells were visualized under UV
light. Magnification, ×100.
|
|
 |
DISCUSSION |
The genetic analysis of a given organism, i.e., the construction
of viral mutants, is the most straightforward way to understand the
function(s) of a given gene in the context of the entire genome. However, the practical realization of these mutants is often quite tedious. Although the genetic complexity of herpesviruses is far from
that encountered in mammalian genomes, the relatively large size of
herpesvirus genomes prevents their conventional cloning. The production
of infectious particles is a recurrent problem when working with EBV or
HHV8. Until now, no cellular system has supported their propagation in
vitro. This renders the construction of viral mutants much more
difficult than with other herpesviruses. In the case of HHV8, even the
identification of infected cells is difficult and often relies on PCR
detection of spliced products (20). The normal counterpart
of the Kaposi's sarcoma spindle cells is still unknown, although they
may be related to the endothelial cells of the vascular or lymphatic
system (8).
As an attempt to circumvent these problems, we have cloned the
whole viral genome onto an F-plasmid that carries the green fluorescent
protein phenotypic marker. This should prove to be helpful for
the identification of HHV8 target cells. The recombinant virus includes
all known sequences, as shown by restriction analyis and subcloning. By
inserting the F-plasmid into ORF56, we interrupted a gene whose EBV
homologue is involved in the viral lytic replication machinery, hoping
to obtain an inducible system. As anticipated, transient transfection
of a plasmid encompassing the disrupted ORF56 gene is able to
complement the defective mutant and suffices to complete the viral
lytic cycle, confirming that the recombinant virus carries
the complete HHV8 genome. Although the ORF56 gene shows homologies to
the EBV protein BSLF1, it cannot be characterized as an immediate-early
gene like BZLF1 in EBV (23). However, the ORF56 gene has
similar functions from a practical point of view. The ability of ORF56
to complement the viral phenotype implies that the 293 cells that carry
the recombinant plasmid spontaneously express some early viral
antigens. In fact, immunostaining using an antibody against the ORF59
early antigen proved that some of the HHV8-positive cells spontaneously
entered the lytic cycle.
The observation that expression of the ORF56 protein leads to
completion of the viral lytic cycle is apparently contradictory to a
report which claims that infection of 293 cells with wild-type HHV8
leads to an abortive lytic viral replication (20). In
fact, cells infected with the HHV8/F-plasmid recombinant did not
produce any progeny, as attested by the absence of propagation in
infected cultures. At this stage, it is only possible to speculate that HHV8 lytic replication must be preceded by a phase of latent infection. However, the molecular mechanisms that control this transition are
still unknown. A similar situation is observed with EBV, with which
cell infection is rarely followed by spontaneous replication, whereas
some cells latently infected with EBV can be induced to produce virions.
The cloning of a complete herpesvirus genome has been valuable for the
modification of several herpesvirus genomes (6, 9, 18, 22,
24). Even deleterious mutations are possible, as we have
demonstrated recently in order to construct the first helper cell line
for the encapsidation of EBV-derived viral vectors (7). As
HHV8 can immortalize endothelial cells in vitro, it is now
theoretically possible to generate viral mutants that have deletions of
one or several genes thought to be involved in cell transformation
(11). Most interesting, the function of a single gene can
be studied in the context of the whole genome. The identification of
the gene products that mediate the transforming potential of HHV8 will
allow the construction of apathogenic strains that are of potential
interest for vaccination of individuals who are at high risk for the
development of Kaposi's sarcoma.
 |
ACKNOWLEDGMENTS |
We thank E. Cesarman (Columbia University, New York) for the BC-3
cell line. We are indebted to R. Sun, Department of Molecular and
Medical Pharmacology, University of California, and Y. Yuan, Dept. of
Microbiology, School of Dental Medicine, University of Pennsylvania,
for providing the HHV8 cosmid GB21.
This work was supported by Public Health Service grant CA70723, grant
Ha 1354/3 from the Deutsche Forschungsgemeinschaft, and grant
10-2016-Ze from the Deutsche Krebshilfe.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: CRC Institute
for Cancer Studies, Department of Pathology, University of Birmingham, B15 2TT Birmingham, United Kingdom. Phone: 44/121/4144496. Fax: 44/121/4144486. E-mail: H.Delecluse{at}bham.ac.uk.
 |
REFERENCES |
| 1.
|
Arvanitakis, L.,
E. Geras-Raaka,
A. Varma,
M. C. Gershengorn, and E. Cesarman.
1997.
Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation.
Nature
385:347-350[CrossRef][Medline].
|
| 2.
|
Arvanitakis, L.,
E. A. Mesri,
R. G. Nador,
J. W. Said,
A. S. Asch,
D. M. Knowles, and E. Cesarman.
1996.
Establishment and characterization of a primary effusion (body cavity- based) lymphoma cell line (BC-3) harboring Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus.
Blood
88:2648-2654[Abstract/Free Full Text].
|
| 3.
|
Bais, C.,
B. Santomasso,
O. Coso,
L. Arvanitakis,
E. G. Raaka,
J. S. Gutkind,
A. S. Asch,
E. Cesarman,
M. C. Gershengorn,
E. A. Mesri, and M. C. Gerhengorn.
1998.
G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator.
Nature
391:86-89[CrossRef][Medline].
|
| 4.
|
Boshoff, C.,
Y. Endo,
P. D. Collins,
Y. Takeuchi,
J. D. Reeves,
V. L. Schweickart,
M. A. Siani,
T. Sasaki,
T. J. Williams,
P. W. Gray,
P. S. Moore,
Y. Chang, and R. A. Weiss.
1997.
Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines.
Science
278:290-294[Abstract/Free Full Text].
|
| 5.
|
Delecluse, H.-J.,
S. Schüller, and W. Hammerschmidt.
1993.
Latent Marek's disease virus can be activated from its chromosomally integrated state in herpesvirus-transformed lymphoma cells.
EMBO J.
12:3277-3286[Medline].
|
| 6.
|
Delecluse, H.-J.,
T. Hilsendegen,
D. Pich,
R. Zeidler, and W. Hammerschmidt.
1998.
Propagation and recovery of intact, infectious Epstein-Barr virus from prckaryotic to human cells.
Proc. Natl. Acad. Sci. USA
95:8245-8250[Abstract/Free Full Text].
|
| 7.
|
Delecluse, H.-J.,
D. Pich,
T. Hilsendegen,
C. Baum, and W. Hammerschmidt.
1999.
A first-generation packaging cell line for Epstein-Barr virus-derived vectors.
Proc. Natl. Acad. Sci. USA
96:5188-5193[Abstract/Free Full Text].
|
| 8.
|
Dupin, N.,
C. Fisher,
P. Kellam,
S. Ariad,
M. Tulliez,
N. Franck,
E. van Marck,
D. Salmon,
I. Gorin,
J. P. Escande,
R. A. Weiss,
K. Alitalo, and C. Boshoff.
1999.
Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma.
Proc. Natl. Acad. Sci. USA
96:4546-4551[Abstract/Free Full Text].
|
| 9.
|
Ensser, A.,
A. Pfinder,
I. Muller-Fleckenstein, and B. Fleckenstein.
1999.
The URNA genes of herpesvirus saimiri (strain C488) are dispensable for transformation of human T cells in vitro.
J. Virol.
73:10551-10555[Abstract/Free Full Text].
|
| 10.
|
Fixman, E. D.,
G. S. Hayward, and S. D. Hayward.
1992.
trans-Acting requirements for replication of Epstein-Barr virus ori-Lyt.
J. Virol.
66:5030-5039[Abstract/Free Full Text].
|
| 11.
|
Flore, O.,
S. Rafii,
S. Ely,
J. J. O'Leary,
E. M. Hyjek, and E. Cesarman.
1998.
Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus.
Nature
394:588-592[CrossRef][Medline].
|
| 12.
|
Gardella, T.,
P. Medveczky,
T. Sairenji, and C. Mulder.
1984.
Detection of circular and linear herpesvirus DNA molecules in mammalian cells by gel electrophoresis.
J. Virol.
50:248-254[Abstract/Free Full Text].
|
| 13.
|
Graham, F. L.,
J. Smiley,
W. C. Russell, and R. Nairn.
1977.
Characteristics of a human cell line transformed by DNA from human adenovirus type 5.
J. Gen. Virol.
36:59-74[Abstract/Free Full Text].
|
| 14.
|
Griffin, B. E.,
E. Björck,
G. Bjursell, and T. Lindahl.
1981.
Sequence complexity of circular Epstein-Barr virus DNA in transformed cells.
J. Virol.
40:11-19[Abstract/Free Full Text].
|
| 15.
|
Klein, G.,
J. Zeuthen,
R. Ber, and I. Ernberg.
1982.
Human lymphoma-lymphoma hybrids and lymphoma-leukemia hybrids. II. Epstein-Barr virus induction patterns.
J. Natl. Cancer Inst.
68:197-202.
|
| 16.
|
Lee, H.,
R. Veazey,
K. Williams,
M. Li,
J. Guo,
F. Neipel,
B. Fleckenstein,
A. Lackner,
R. C. Desrosiers, and J. U. Jung.
1998.
Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus.
Nat. Med.
4:435-440[CrossRef][Medline].
|
| 17.
|
Luka, J.,
B. Kallin, and G. Klein.
1979.
Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate.
Virology
94:228-231[CrossRef][Medline].
|
| 18.
|
Messerle, M.,
I. Crnkovic,
W. Hammerschmidt,
H. Ziegler, and U. H. Koszinowski.
1997.
Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome.
Proc. Natl. Acad. Sci. USA
94:14759-14763[Abstract/Free Full Text].
|
| 19.
|
Moore, P. S.,
C. Boshoff,
R. A. Weiss, and Y. Chang.
1996.
Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV.
Science
274:1739-1744[Abstract/Free Full Text].
|
| 20.
|
Renne, R.,
D. Blackbourn,
D. Whitby,
J. Levy, and D. Ganem.
1998.
Limited transmission of Kaposi's sarcoma-associated herpesvirus in cultured cells.
J. Virol.
72:5182-5188[Abstract/Free Full Text].
|
| 21.
|
Russo, J. J.,
R. A. Bohenzky,
M. C. Chien,
J. Chen,
M. Yan,
D. Maddalena,
J. P. Parry,
D. Peruzzi,
I. S. Edelman,
Y. Chang, and P. S. Moore.
1996.
Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8).
Proc. Natl. Acad. Sci. USA
93:14862-14867[Abstract/Free Full Text].
|
| 22.
|
Smith, G. A., and L. W. Enquist.
2000.
A self-recombining bacterial artificial chromosome and its application for analysis of herpesvirus pathogenesis.
Proc. Natl. Acad. Sci. USA
97:4873-4878[Abstract/Free Full Text].
|
| 23.
|
Speck, S. H.,
T. Chatila, and E. Flemington.
1997.
Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene.
Trends Microbiol.
5:399-405[CrossRef][Medline].
|
| 24.
|
Suter, M.,
A. M. Lew,
P. Grob,
G. J. Adema,
M. Ackermann,
K. Shortman, and C. Fraefel.
1999.
BAC-VAC, a novel generation of (DNA) vaccines: A bacterial artificial chromosome (BAC) containing a replication-competent, packaging-defective virus genome induces protective immunity against herpes simplex virus 1.
Proc. Natl. Acad. Sci. USA
96:12697-12702[Abstract/Free Full Text].
|
| 25.
|
Swanton, C.,
D. J. Mann,
B. Fleckenstein,
F. Neipel,
G. Peters, and N. Jones.
1997.
Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins.
Nature
390:184-187[CrossRef][Medline].
|
| 26.
|
Thome, M.,
P. Schneider,
K. Hofmann,
H. Fickenscher,
E. Meinl,
F. Neipel,
C. Mattmann,
K. Burns,
J. L. Bodmer,
M. Schroter,
C. Scaffidi,
P. H. Krammer,
M. E. Peter, and J. Tschopp.
1997.
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors.
Nature
386:517-521[CrossRef][Medline].
|
| 27.
|
zur Hausen, H.,
F. J. O'Neill, and U. K. Freese.
1978.
Persisting oncogenic herpesvirus induced by tumour promoter TPA.
Nature
272:373-375[CrossRef][Medline].
|
Journal of Virology, March 2001, p. 2921-2928, Vol. 75, No. 6
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.6.2921-2928.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Majerciak, V., Pripuzova, N., McCoy, J. P., Gao, S.-J., Zheng, Z.-M.
(2007). Targeted Disruption of Kaposi's Sarcoma-Associated Herpesvirus ORF57 in the Viral Genome Is Detrimental for the Expression of ORF59, K8{alpha}, and K8.1 and the Production of Infectious Virus. J. Virol.
81: 1062-1071
[Abstract]
[Full Text]
-
Duus, K. M., Lentchitsky, V., Wagenaar, T., Grose, C., Webster-Cyriaque, J.
(2004). Wild-Type Kaposi's Sarcoma-Associated Herpesvirus Isolated from the Oropharynx of Immune-Competent Individuals Has Tropism for Cultured Oral Epithelial Cells. J. Virol.
78: 4074-4084
[Abstract]
[Full Text]
-
White, R. E., Calderwood, M. A., Whitehouse, A.
(2003). Generation and precise modification of a herpesvirus saimiri bacterial artificial chromosome demonstrates that the terminal repeats are required for both virus production and episomal persistence. J. Gen. Virol.
84: 3393-3403
[Abstract]
[Full Text]
-
Dourmishev, L. A., Dourmishev, A. L., Palmeri, D., Schwartz, R. A., Lukac, D. M.
(2003). Molecular Genetics of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Epidemiology and Pathogenesis. Microbiol. Mol. Biol. Rev.
67: 175-212
[Abstract]
[Full Text]
-
Bechtel, J. T., Liang, Y., Hvidding, J., Ganem, D.
(2003). Host Range of Kaposi's Sarcoma-Associated Herpesvirus in Cultured Cells. J. Virol.
77: 6474-6481
[Abstract]
[Full Text]
-
Zhou, F.-C., Zhang, Y.-J., Deng, J.-H., Wang, X.-P., Pan, H.-Y., Hettler, E., Gao, S.-J.
(2002). Efficient Infection by a Recombinant Kaposi's Sarcoma-Associated Herpesvirus Cloned in a Bacterial Artificial Chromosome: Application for Genetic Analysis. J. Virol.
76: 6185-6196
[Abstract]
[Full Text]
-
Hyun, T. S., Subramanian, C., Cotter, M. A. II, Thomas, R. A., Robertson, E. S.
(2001). Latency-Associated Nuclear Antigen Encoded by Kaposi's Sarcoma-Associated Herpesvirus Interacts with Tat and Activates the Long Terminal Repeat of Human Immunodeficiency Virus Type 1 in Human Cells. J. Virol.
75: 8761-8771
[Abstract]
[Full Text]